Serge N. Manié

TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.

TL;DR: The current knowledge of the UPR during oncogenesis, tumour growth, metastasis and chemoresistance is discussed, with a focus on the role of IRE1, PERK and ATF6.

TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis

TL;DR: It is proposed that CDYL2 contributes to poor prognosis in breast cancer by recruiting G9a and EZH2 to epigenetically repress MIR124 genes, thereby promoting NF-κB and STAT3 signaling, as well as downstream cancer cell plasticity and malignant progression.

TL;DR: In GI-NET cell lines, UPR signaling is functional and PERK arm is induced by mTOR inhibition, indicating that mTOR drives a PERK-dependent survival pathway, and the crosstalk between mTOR and UPR might contribute to the resistance to mTOR inhibitors and could be targeted by m TOR and PERk inhibitors in combination therapy.